Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Eli Lilly and CompanyNYSE: LLY

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures growth accelerates

Q2 FY2026 capital expenditures of $2.93B (cash outflow) rose 62.6% year over year, ahead of the -26.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 26.1% from the prior quarter. Over 3 fiscal years it compounded at +38.0% a year.

Context

  • Capital expenditures amounted to 12.0% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +62.6% holds above the trailing-twelve-month pace of -26.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.93B+26.1% QoQ
Last fiscal yearDec 2025
-$7.84B+55.0% YoY
LTMJun 2026
-$8.03B-26.9% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+62.6%——
1 year+55.0%——
3-year CAGR+38.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(7.84B) USD
Year-over-year change
-55.0%

Capital Expenditures vs competitors

How LLY compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.9% is the 7th highest of 9, against a peer median of +5.5%.
  • Capital expenditures amounts to 10.1% of revenue for LLY, versus a peer median of 5.6%.
LLY Competitors
Capital Expenditures for LLY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 84.09B DKK+40.3%+82.8%25.5%
LLYEli Lilly and CompanyLTM Jun 2026$8.03B USD-26.9%+38.0%10.1%
JNJJohnson & JohnsonLTM Sep 2026$5.57B USD+8.6%+6.4%5.6%
AZNAstraZeneca PLCLTM Sep 2026$4.01B USD-28.0%+31.9%6.5%
MRKMerck & Co., Inc.LTM Jun 2026$3.9B USD+2.4%-2.1%5.9%
NVSNovartis AGLTM Jun 2026$2.57B USD-35.5%-11.4%4.6%
SNYSanofiLTM Jun 2026€2.52B EUR—-1.8%5.2%
PFEPfizer Inc.LTM Jun 2026$2.42B USD-12.1%-6.7%3.8%
AMGNAmgen Inc.LTM Jun 2026$2.3B USD+63.6%+25.7%6.0%
ABBVAbbVie Inc.LTM Jun 2026$1.3B USD+24.2%+20.4%2.0%
Peer median (excluding LLY) —+5.5%+6.4%5.6%

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.58B6.24B5.24B10.59B20.64B
Depreciation & Amortization1.55B1.52B1.53B1.77B2B
Deferred Income Tax(802.3M)(2.19B)(2.34B)(2.68B)(1.71B)
Stock-Based Compensation342.8M371.1M628.5M645.6M626M
Change in Working Capital(1.01B)(800K)(3.06B)(5.39B)(8.09B)
Accounts Receivables(1.28B)(299.6M)(2.45B)(2.16B)(7B)
Inventory(235.9M)(599.7M)(1.43B)(2.51B)(4.67B)
Accounts Payables(1.01B)1.33B4.27B2.61B10.19B
Other Working Capital1.52B(433.2M)(3.45B)(3.33B)(6.61B)
Other Non-Cash Items1.71B1.63B2.24B3.88B3.35B
Operating Cash Flow7.37B7.59B4.24B8.82B16.81B
Capital Expenditures(1.98B)(2.99B)(7.39B)(5.06B)(7.84B)
Acquisitions (Net)(747.4M)(327.2M)(1.04B)(947.7M)(661M)
Purchases of Investments(1.01B)(707.6M)(829M)(775.8M)(645M)
Sales of Investments847.4M463.6M700.3M522.5M964M
Other Investing Activities(644.3M)(1.34B)(2.53B)303.1M(2.79B)
Investing Cash Flow(2.87B)(3.76B)(7.15B)(9.3B)(10.97B)
Debt Repayment501.4M(62M)8.65B8.9B8.05B
Common Stock Issued00000
Common Stock Repurchased(1.25B)(1.5B)(750M)(2.5B)(4.11B)
Dividends Paid(3.09B)(3.54B)(4.07B)(4.68B)(5.38B)
Other Financing Activities(295.9M)(308.9M)(335M)(490.6M)(772M)
Financing Cash Flow(4.13B)(5.41B)3.5B1.23B(2.21B)
Effect of Forex Changes(205.7M)(167.6M)168.6M(296.7M)372M
Net Change in Cash161.4M(1.75B)751.6M449.8M4B
Free Cash Flow5.39B4.6B(3.15B)3.76B8.97B

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.